Background: The Val-MARC trial showed that the angiotensin receptor blocker valsartan reduces high-sensitivity C reactive protein (hsCRP) levels, an effect that is independent of blood pressure, and seems to be neutralised by the addition of hydrochlorothiazide.
Objective: To evaluate whether valsartan influences soluble intercellular adhesion molecule 1 (sICAM-1) or vascular cell adhesion molecule 1 (sVCAM-1).
Design: Post-hoc analysis from a randomised trial.
Setting: Val-MARC trial.
Patients: 1188 patients with stage 2 hypertension.
Intervention: Random allocation to either valsartan 320 mg (n = 607) or combination therapy with valsartan/hydrochlorothiazide 320 mg/12.5 mg (n = 581) for 6 weeks.
Main outcome measure: Change in sICAM-1 and sVCAM-1 from baseline to 6 weeks of follow-up
Results: After treatment, median (interquartile range) sICAM-1 levels were reduced by both valsartan alone (−4 (−25 to 16) ng/ml, p = 0.005) and valsartan/hydrochlorothiazide (−4 (−22 to 17) ng/ml, p = 0.028), such that the between-group difference was not significant (p = 0.7). The median percentage change from baseline was small in both groups (−1.6% and −1.3%). Median (interquartile range) sVCAM-1 levels were reduced by both valsartan alone (−13 (−70 to 42) ng/ml, p = 0.001) and valsartan/hydrochlorothiazide (−26 (−88 to 38), p<0.001); the between-group difference was of borderline significance (p = 0.051). The median percentage change from baseline was small (−2.1% and −4.4%). The reduction of sICAM-1 and sVCAM-1 was independent of blood pressure reduction (rs = 0.03 and rs = 0.06 for the relationship of change in systolic blood pressure with change in sICAM-1 and sVCAM-1, respectively).
Conclusion: In contrast to hsCRP, both valsartan and valsartan/hydrochlorothiazide induced reductions of sICAM-1 and sVCAM-1 in the Val-MARC trial. These effects, although statistically significant, were small and independent of changes in blood pressure.
Statistics from Altmetric.com
Funding: The Val-MARC trial was funded by Novartis. DC is supported by grants of the Swiss National Science Foundation (PBBSB-113207) and the Janggen-Poehn Foundation, St. Gallen, Switzerland.
Competing interests: PMR is listed as a coinventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease.
Ethics approval: Obtained.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.